Compare D R Horton Inc (DHI) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? D R Horton Inc trades at $150 (market cap $42.53B), while Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M). The key difference: D R Horton Inc is far larger — about 72× Ginkgo Bioworks Holdings Inc's market cap, and D R Horton Inc pays a 1.2% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DHI | DNA | |
|---|---|---|
Market Cap | $42.53B | $590.53M |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $16.14 |
52-Week Low | $129.82 | $5.48 |
Enterprise Value | $47.25B | $627.78M |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $148.85, down 1.8% over 24 hours, with a bearish technical signal from moving averages but oversold RSI levels. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025, with revenue declining to $34.25 billion in 2025. Analyst consensus is split between Buy and Hold ratings, with a $164.71 price target suggesting potential upside. Recent news highlights housing market headwinds from rising mortgage rates but also potential support from new legislation.
DHI presents a cautious opportunity with attractive valuation multiples (P/E 13.98, P/S 1.32) and a stable dividend, but faces risks from housing affordability pressures and volatile cash flows. Investors should weigh the company's scale and market position against macroeconomic challenges in the homebuilding sector.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
